Table 2. Relationship between ING5 expression and clinicopathological features of breast cancer.

Clinicopathological	n	Nuclear ING5 expression						Cytoplasmic ING5 expression
features		–	+	++	+++	PR(%)	p	–	+	++	+++	PR(%)	p
Age (years)
< 45	58	7	15	18	18	87.9	0.648	11	36	10	1	81.0	0.165
≥ 45	202	17	45	83	57	91.6		43	91	56	12	78.7
Tumor size (cm)
< 2.5	93	9	19	37	28	90.3		20	48	23	2	78.5
≥ 2.5	89	6	19	36	28	93.3	0.709	11	39	29	10	87.6	0.005
Pathological classification
Invasive ductal cancer	182	17	37	73	55	90.7	0.657	34	86	50	12	81.3	0.189
Invasive lobular cancer	9	1	2	4	2	88.9		4	3	1	1	55.6
Lymphatic vessel invasion
+	19	2	3	8	6	89.5	0.701	1	12	4	2	94.7	0.569
–	54	0	14	21	19	100.0		9	26	19	0	83.3
Lymph node metastasis
+	115	10	26	45	34	91.3	0.812	27	53	27	8	76.5	0.977
–	138	14	31	53	40	89.9		28	70	35	5	79.7
Distant metastasis
+	10	2	5	3	0	80.0	0.026	3	6	1	0	70.0	0.605
–	82	9	22	26	25	89.0		25	38	14	5	69.5
TNM staging
I–II	118	18	25	43	32	84.7		30	51	29	8	74.6
III–IV	31	3	11	13	4	90.3	0.284	9	16	4	2	71.0	0.330
ER expression
+	104	8	19	50	27	92.3	0.293	16	52	31	5	84.6	0.044
–	142	17	37	48	40	88.0		36	70	29	7	74.6
PR expression
+	90	6	16	45	23	93.3	0.281	14	46	26	4	84.4	0.146
–	155	18	40	53	44	88.4		37	76	34	8	76.1
Her2 expression
+	93	9	17	42	25	90.3	0.586	15	50	26	2	83.9	0.452
–	150	15	38	55	42	90.0		36	71	33	10	76.0
p53 expression
+	68	1	11	26	30	98.5	0.035	11	34	20	3	83.8	0.887
–	32	1	8	16	7	96.9		2	21	8	1	93.8
Ki-67 percentage(%)
< 50	138	13	23	62	40	90.6	0.648	22	68	43	5	84.1	0.473
≥ 50	23	1	5	9	8	95.7		3	11	6	3	87.0
Triple-negative breast cancer
+	92	10	28	29	25	89.1	0.117	28	44	15	5	69.6	0.008
–	168	14	32	72	50	91.7		26	83	51	8	84.5

PR , positive rate; TNM, tumor node metastasis; ER, estrogen receptor; PR, progesterone receptor.